Status:
COMPLETED
Ivermectin in the Treatment of Head Lice
Lead Sponsor:
Johnson & Johnson Consumer and Personal Products Worldwide
Conditions:
Lice Infestations
Eligibility:
All Genders
2+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare 2 single doses of ivermectin as tablets with 2 single applications of malathion 0.5% lotion (Days 1 and 8) in clearing head lice, in patients who have recently ...
Detailed Description
Head lice infestation occurs frequently, primarily in children 3 to 11 years of age. In recent years an increasing prevalence of lice infestation in schools, day care centres, and summer day camps is ...
Eligibility Criteria
Inclusion
- Head lice infestation confirmed by detection combing by study staff
- previous (within 6 weeks) use of a topical insecticide product
- minimum 15kg weight
- providing informed consent
Exclusion
- pregnant or nursing patients
- households with 7 or more infested patients
- households where there are other known infested household members not participating
- head lice treatment within 2 weeks of entry
- active scalp infection
- any difficulty with combing assessment
- patient from region endemic for certain parasitic worm diseases
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2004
Estimated Enrollment :
812 Patients enrolled
Trial Details
Trial ID
NCT00819520
Start Date
February 1 2004
End Date
October 1 2004
Last Update
August 22 2011
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Avicenne
Bobigny, Paris, France, 93009
2
Shandon Clinic
Cork, Co. Cork, Ireland
3
Chaim Sheba Medical Centre
Tel Litwinsky, Tel Hashomer, Israel, 52621
4
Synexus Clinical Research Centre
Reading, Berks, United Kingdom, RG2 7AG